{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:52:39Z","timestamp":1781898759373,"version":"3.54.5"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11064-025-04399-7","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T19:18:53Z","timestamp":1744831133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Unravelling the Proteinopathic Engagement of \u03b1-Synuclein, Tau, and Amyloid Beta in Parkinson\u2019s Disease: Mitochondrial Collapse as a Pivotal Driver of Neurodegeneration"],"prefix":"10.1007","volume":"50","author":[{"given":"Tarini Ashish","family":"Sahoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdish","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarjith Thiyyar","family":"Kandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanish","family":"Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gomathy","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"4399_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3988\/jcn.2022.18.3.259","volume":"18","author":"HW Shin","year":"2022","unstructured":"Shin HW, Hong SW, Youn YC (2022) Clinical aspects of the differential diagnosis of Parkinson\u2019s disease and Parkinsonism. J Clin Neurol (Korea) 18:259\u2013270. https:\/\/doi.org\/10.3988\/jcn.2022.18.3.259","journal-title":"J Clin Neurol (Korea)"},{"key":"4399_CR2","doi-asserted-by":"publisher","first-page":"113718","DOI":"10.1016\/j.biopha.2022.113718","volume":"155","author":"M Pang","year":"2022","unstructured":"Pang M, Peng R, Wang Y et al (2022) Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson\u2019s disease. Biomed Pharmacother 155:113718","journal-title":"Biomed Pharmacother"},{"key":"4399_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2011.04.016","volume":"310","author":"H Reichmann","year":"2011","unstructured":"Reichmann H (2011) View point: Etiology in Parkinson\u2019s disease. Dual hit or spreading intoxication. J Neurol Sci 310:9\u201311. https:\/\/doi.org\/10.1016\/j.jns.2011.04.016","journal-title":"J Neurol Sci"},{"issue":"10","key":"4399_CR4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/sj.cdd.4400432","volume":"5","author":"JQ Trojanowski","year":"1998","unstructured":"Trojanowski JQ, Goedert M, Iwatsubo T, Lee MY (1998) Fatal attractions: abnormal protein aggregation and neuron death in Parkinson\u2019s disease and Lewy body dementia. Cell Death Differ 5(10):832\u2013837","journal-title":"Cell Death Differ"},{"key":"4399_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.parkreldis.2004.01.001","volume":"10","author":"GE Meredith","year":"2004","unstructured":"Meredith GE, Halliday GM, Totterdell S (2004) A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson\u2019s disease: new insights into Lewy body formation. Parkinsonism Relat Disord 10:191\u2013202","journal-title":"Parkinsonism Relat Disord"},{"key":"4399_CR6","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.3390\/biomedicines10123241","volume":"10","author":"A Surguchov","year":"2022","unstructured":"Surguchov A, Surguchev A (2022) Synucleins: new data on misfolding. Aggregation and role in diseases. Biomedicines 10:3241","journal-title":"Biomedicines"},{"issue":"7933","key":"4399_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","volume":"610","author":"Y Yang","year":"2022","unstructured":"Yang Y, Shi Y, Schweighauser M et al (2022) Structures of \u03b1-synuclein filaments from human brains with Lewy pathology Europe PMC Funders Group. Nature 610(7933):791\u2013795","journal-title":"Nature"},{"key":"4399_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/brain\/awad388","volume":"147","author":"Y Chu","year":"2024","unstructured":"Chu Y, Hirst WD, Federoff HJ et al (2024) Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain 147:444\u2013457. https:\/\/doi.org\/10.1093\/brain\/awad388","journal-title":"Brain"},{"key":"4399_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1445-5994.2006.01153.x","volume":"36","author":"DR Williams","year":"2006","unstructured":"Williams DR (2006) Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 36:652\u2013660","journal-title":"Intern Med J"},{"key":"4399_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/fneur.2018.00809","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Gao F, Wang D et al (2018) Tau pathology in Parkinson\u2019s disease. Front Neurol 9:809","journal-title":"Front Neurol"},{"key":"4399_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1386608","author":"R Bhidayasiri","year":"2024","unstructured":"Bhidayasiri R, Sringean J, Phumphid S et al (2024) The rise of Parkinson\u2019s disease is a global challenge, but efforts to tackle this must begin at a national level: a protocol for national digital screening and \u201ceat, move, sleep\u201d lifestyle interventions to prevent or slow the rise of non-communicable diseases in Thailand. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2024.1386608","journal-title":"Front Neurol"},{"key":"4399_CR12","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2666-7568(24)00094-1","volume":"5","author":"J Zhu","year":"2024","unstructured":"Zhu J, Cui Y, Zhang J et al (2024) Temporal trends in the prevalence of Parkinson\u2019s disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev 5:e464\u2013e479. https:\/\/doi.org\/10.1016\/S2666-7568(24)00094-1","journal-title":"Lancet Healthy Longev"},{"key":"4399_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912","journal-title":"Lancet"},{"key":"4399_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s11064-014-1507-8","volume":"40","author":"L Liu","year":"2015","unstructured":"Liu L, Peritore C, Ginsberg J et al (2015) SIRT3 attenuates MPTP-induced nigrostriatal degeneration via enhancing mitochondrial antioxidant capacity. Neurochem Res 40:600\u2013608. https:\/\/doi.org\/10.1007\/s11064-014-1507-8","journal-title":"Neurochem Res"},{"key":"4399_CR15","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.3233\/JAD-220449","volume":"94","author":"KP Tryphena","year":"2023","unstructured":"Tryphena KP, Anuradha U, Kumar R et al (2023) Understanding the involvement of microRNAs in mitochondrial dysfunction and their role as potential biomarkers and therapeutic targets in Parkinson\u2019s disease. J Alzheimer\u2019s Dis 94:S187\u2013S202","journal-title":"J Alzheimer\u2019s Dis"},{"key":"4399_CR16","doi-asserted-by":"publisher","first-page":"845618","DOI":"10.1155\/2012\/845618","volume":"2012","author":"J Blesa","year":"2012","unstructured":"Blesa J, Phani S, Jackson-Lewis V, Przedborski S (2012) Classic and new animal models of Parkinson\u2019s disease. J Biomed Biotechnol 2012:845618","journal-title":"J Biomed Biotechnol"},{"key":"4399_CR17","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","volume":"25","author":"C Pacelli","year":"2015","unstructured":"Pacelli C, Gigu\u00e8re N, Bourque MJ et al (2015) Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol 25:2349\u20132360. https:\/\/doi.org\/10.1016\/j.cub.2015.07.050","journal-title":"Curr Biol"},{"key":"4399_CR18","first-page":"406","volume":"60 Suppl 4","author":"N Hattori","year":"2002","unstructured":"Hattori N, Mizuno Y (2002) Mitochondrial dysfunction in Parkinson\u2019s disease. Nippon rinsho. Jpn J Clin Med 60 Suppl 4:406\u2013411","journal-title":"Jpn J Clin Med"},{"key":"4399_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","volume":"10","author":"S Ramesh","year":"2023","unstructured":"Ramesh S, Arachchige ASPM (2023) Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: a review of the literature. AIMS Neurosci 10:200\u2013231","journal-title":"AIMS Neurosci"},{"issue":"10","key":"4399_CR20","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/biom11101508","volume":"11","author":"A Picca","year":"2021","unstructured":"Picca A, Guerra F, Calvani R et al (2021) Mitochondrial dysfunction, protein misfolding and neuroinflammation in parkinson\u2019s disease: roads to biomarker discovery. Biomolecules 11(10):1508","journal-title":"Biomolecules"},{"key":"4399_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009399","author":"L Stefanis","year":"2012","unstructured":"Stefanis L (2012) \u03b1-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a009399","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4399_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bj.2018.03.004","volume":"41","author":"R Farah","year":"2018","unstructured":"Farah R, Haraty H, Salame Z et al (2018) Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed J 41:63\u201387","journal-title":"Biomed J"},{"key":"4399_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.61951","volume":"10","author":"RS Jacob","year":"2021","unstructured":"Jacob RS, Eichmann C, Dema A et al (2021) \u03b1-Synuclein plasma membrane localization correlates with cellular phosphatidylinositol polyphosphate levels. Elife 10:1\u201355. https:\/\/doi.org\/10.7554\/eLife.61951","journal-title":"Elife"},{"key":"4399_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.arr.2015.12.002","volume":"26","author":"N Plotegher","year":"2016","unstructured":"Plotegher N, Bubacco L (2016) Lysines, Achilles\u2019 heel in alpha-synuclein conversion to a deadly neuronal endotoxin. Ageing Res Rev 26:62\u201371","journal-title":"Ageing Res Rev"},{"key":"4399_CR25","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41593-022-01140-3","volume":"25","author":"ML Choi","year":"2022","unstructured":"Choi ML, Chappard A, Singh BP et al (2022) Pathological structural conversion of \u03b1-synuclein at the mitochondria induces neuronal toxicity. Nat Neurosci 25:1134\u20131148. https:\/\/doi.org\/10.1038\/s41593-022-01140-3","journal-title":"Nat Neurosci"},{"key":"4399_CR26","doi-asserted-by":"crossref","unstructured":"Kapu S, Varkey J An examination of post-translational modifications of \u03b1-synuclein and its effects on Parkinson\u2019s disease. Archives 13(2):","DOI":"10.47611\/jsrhs.v13i2.6807"},{"key":"4399_CR27","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201512016","author":"YJ Chai","year":"2016","unstructured":"Chai YJ, Sierecki E, Tomatis VM et al (2016) Munc18-1 is a molecular chaperone for \u03b1-synuclein, controlling its self-replicating aggregation. J Cell Biol. https:\/\/doi.org\/10.1083\/jcb.201512016","journal-title":"J Cell Biol"},{"key":"4399_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000007786","volume":"93","author":"V Lanoue","year":"2019","unstructured":"Lanoue V, Chai YJ, Brouillet JZ et al (2019) STXBP1 encephalopathy: connecting neurodevelopmental disorders with \u03b1-synucleinopathies? Neurology 93:114\u2013123","journal-title":"Neurology"},{"key":"4399_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi JC, Hirth F (2018) Mechanisms of \u03b1-synuclein induced synaptopathy in Parkinson\u2019s disease. Front Neurosci. 12:80","journal-title":"Front Neurosci."},{"key":"4399_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195339","author":"MG Choi","year":"2018","unstructured":"Choi MG, Kim MJ, Kim DG et al (2018) Sequestration of synaptic proteins by alphasynuclein aggregates leading to neurotoxicity is inhibited by small peptide. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0195339","journal-title":"PLoS ONE"},{"key":"4399_CR31","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1073\/pnas.1218424110","volume":"110","author":"BK Choi","year":"2013","unstructured":"Choi BK, Choi MG, Kim JY et al (2013) Large \u03b1-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci USA 110:4087\u20134092. https:\/\/doi.org\/10.1073\/pnas.1218424110","journal-title":"Proc Natl Acad Sci USA"},{"key":"4399_CR32","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1289\/ehp.1003013","volume":"119","author":"HM Gao","year":"2011","unstructured":"Gao HM, Zhang F, Zhou H et al (2011) Neuroinflammation and \u03b1-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson\u2019s disease. Environ Health Perspect 119:807\u2013814. https:\/\/doi.org\/10.1289\/ehp.1003013","journal-title":"Environ Health Perspect"},{"issue":"17","key":"4399_CR33","doi-asserted-by":"publisher","first-page":"9197","DOI":"10.3390\/ijms25179197","volume":"25","author":"D Krawczuk","year":"2024","unstructured":"Krawczuk D, Groblewska M, Mroczko J et al (2024) The role of \u03b1-synuclein in etiology of neurodegenerative diseases. Int J Mol Sci 25(17):9197","journal-title":"Int J Mol Sci"},{"key":"4399_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/mp.2015.23","volume":"21","author":"G Jun","year":"2016","unstructured":"Jun G, Ibrahim-Verbaas CA, Vronskaya M et al (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108\u2013117. https:\/\/doi.org\/10.1038\/mp.2015.23","journal-title":"Mol Psychiatry"},{"key":"4399_CR35","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1002\/alz.13784","volume":"20","author":"S Buchholz","year":"2024","unstructured":"Buchholz S, Zempel H (2024) The six brain-specific TAU isoforms and their role in Alzheimer\u2019s disease and related neurodegenerative dementia syndromes. Alzheimer\u2019s Dementia 20:3606\u20133628","journal-title":"Alzheimer\u2019s Dementia"},{"key":"4399_CR36","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1073\/pnas.1504081112","volume":"112","author":"H Kadavath","year":"2015","unstructured":"Kadavath H, Hofele RV, Biernat J et al (2015) Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci USA 112:7501\u20137506. https:\/\/doi.org\/10.1073\/pnas.1504081112","journal-title":"Proc Natl Acad Sci USA"},{"key":"4399_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnagi.2019.00204","volume":"11","author":"P Barbier","year":"2019","unstructured":"Barbier P, Zejneli O, Martinho M et al (2019) Role of tau as a microtubule-associated protein: Structural and functional aspects. Front Aging Neurosci 11:204","journal-title":"Front Aging Neurosci"},{"key":"4399_CR38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1523\/JNEUROSCI.3029-15.2016","volume":"36","author":"S Meier","year":"2016","unstructured":"Meier S, Bell M, Lyons DN et al (2016) Pathological tau promotes neuronal damage by impairing ribosomal function and decreasing protein synthesis. J Neurosci 36:957\u2013962. https:\/\/doi.org\/10.1523\/JNEUROSCI.3029-15.2016","journal-title":"J Neurosci"},{"key":"4399_CR39","doi-asserted-by":"publisher","first-page":"1432002","DOI":"10.3389\/fncel.2024.1432002","volume":"18","author":"SSK Durairajan","year":"2024","unstructured":"Durairajan SSK, Selvarasu K, Singh AK et al (2024) Unraveling the interplay of kinesin-1, tau, and microtubules in neurodegeneration associated with Alzheimer\u2019s disease. Front Cell Neurosci 18:1432002","journal-title":"Front Cell Neurosci"},{"issue":"29","key":"4399_CR40","doi-asserted-by":"publisher","first-page":"eabo4459","DOI":"10.1126\/sciadv.abo4459","volume":"8","author":"N El Mammeri","year":"2022","unstructured":"El Mammeri N, Dregni AJ, Duan P et al (2022) Microtubule-binding core of the tau protein. Sci Adv 8(29):eabo4459","journal-title":"Sci Adv"},{"key":"4399_CR41","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/0896-6273(89)90050-0","volume":"2","author":"G Lee","year":"1989","unstructured":"Lee G, Neve R, Kosik K (1989) The microtubule binding of Tau protein. Neuron 2:1615\u20131624","journal-title":"Neuron"},{"key":"4399_CR42","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1242\/jcs.120832","volume":"126","author":"G Breuzard","year":"2013","unstructured":"Breuzard G, Hubert P, Nouar R et al (2013) Molecular mechanisms of Tau binding to microtubules and its role in microtubule dynamics in live cells. J Cell Sci 126:2810\u20132819. https:\/\/doi.org\/10.1242\/jcs.120832","journal-title":"J Cell Sci"},{"key":"4399_CR43","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.neurobiolaging.2007.05.002","volume":"29","author":"TM Caffrey","year":"2008","unstructured":"Caffrey TM, Joachim C, Wade-Martins R (2008) Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus. Neurobiol Aging 29:1923\u20131929. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.05.002","journal-title":"Neurobiol Aging"},{"issue":"5","key":"4399_CR44","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/cells11050840","volume":"11","author":"D Ruiz-Gabarre","year":"2022","unstructured":"Ruiz-Gabarre D, Carnero-Espejo A, \u00c1vila J, Garc\u00eda-Escudero V (2022) What\u2019s in a gene? The outstanding diversity of MAPT. Cells 11(5):840","journal-title":"Cells"},{"key":"4399_CR45","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1093\/hmg\/ddp264","volume":"18","author":"T Rodriguez-Martin","year":"2009","unstructured":"Rodriguez-Martin T, Anthony K, Garcia-Blanco MA et al (2009) Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing. Hum Mol Genet 18:3266\u20133273. https:\/\/doi.org\/10.1093\/hmg\/ddp264","journal-title":"Hum Mol Genet"},{"key":"4399_CR46","first-page":"731526","volume":"2012","author":"M Kolarova","year":"2012","unstructured":"Kolarova M, Garc\u00eda-Sierra F, Bartos A et al (2012) Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012:731526","journal-title":"Int J Alzheimers Dis"},{"key":"4399_CR47","doi-asserted-by":"publisher","first-page":"20711","DOI":"10.1074\/jbc.M112.364067","volume":"287","author":"Q Zhong","year":"2012","unstructured":"Zhong Q, Congdon EE, Nagaraja HN, Kuret J (2012) Tau isoform composition influences rate and extent of filament formation. J Biol Chem 287:20711\u201320719. https:\/\/doi.org\/10.1074\/jbc.M112.364067","journal-title":"J Biol Chem"},{"key":"4399_CR48","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fnagi.2016.00262","volume":"8","author":"J Avila","year":"2016","unstructured":"Avila J, Jim\u00e9nez JS, Sayas CL et al (2016) Tau structures. Front Aging Neurosci 8:262","journal-title":"Front Aging Neurosci"},{"key":"4399_CR49","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1093\/hmg\/ddab360","volume":"31","author":"R Kandimalla","year":"2022","unstructured":"Kandimalla R, Manczak M, Pradeepkiran JA et al (2022) A partial reduction of Drp1 improves cognitive behavior and enhances mitophagy, autophagy and dendritic spines in a transgenic Tau mouse model of Alzheimer disease. Hum Mol Genet 31:1788\u20131805. https:\/\/doi.org\/10.1093\/hmg\/ddab360","journal-title":"Hum Mol Genet"},{"key":"4399_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17:5\u201321","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"4399_CR51","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1083\/jcb.115.3.717","volume":"115","author":"KA Butner","year":"1991","unstructured":"Butner KA, Krischner MW (1991) Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol 115(3):717\u2013730","journal-title":"J Cell Biol"},{"key":"4399_CR52","doi-asserted-by":"crossref","unstructured":"Biswas S, Grover R, Reuther C et al (2024) Tau accelerates tubulin exchange in the microtubule lattice","DOI":"10.1101\/2024.10.05.616777"},{"key":"4399_CR53","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","volume":"28","author":"N Basheer","year":"2023","unstructured":"Basheer N, Smolek T, Hassan I et al (2023) Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From preclinical studies to the clinical trials. Mol Psychiatry 28:2197\u20132214","journal-title":"Mol Psychiatry"},{"issue":"21","key":"4399_CR54","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat P, Sehar U, Bisht J et al (2022) Phosphorylated Tau in Alzheimer\u2019s disease and other tauopathies. Int J Mol Sci 23(21):12841","journal-title":"Int J Mol Sci"},{"key":"4399_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fncel.2018.00338","volume":"12","author":"AD Alonso","year":"2018","unstructured":"Alonso AD, Cohen LS, Corbo C et al (2018) Hyperphosphorylation of Tau Associates with changes in its function beyond microtubule stability. Front Cell Neurosci 12:338","journal-title":"Front Cell Neurosci"},{"key":"4399_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2019.00057","author":"M Luppi","year":"2019","unstructured":"Luppi M, Hitrec T, Di Cristoforo A et al (2019) Phosphorylation and dephosphorylation of tau protein during synthetic torpor. Front Neuroanat. https:\/\/doi.org\/10.3389\/fnana.2019.00057","journal-title":"Front Neuroanat"},{"key":"4399_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fnmol.2014.00065","volume":"7","author":"T Kimura","year":"2014","unstructured":"Kimura T, Ishiguro K, Hisanaga SI (2014) Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci 7:65","journal-title":"Front Mol Neurosci"},{"key":"4399_CR58","doi-asserted-by":"publisher","first-page":"974414","DOI":"10.3389\/fnagi.2022.974414","volume":"14","author":"NA Jackson","year":"2022","unstructured":"Jackson NA, Guerrero-Mu\u00f1oz MJ, Castillo-Carranza DL (2022) The prion-like transmission of tau oligomers via exosomes. Front Aging Neurosci 14:974414","journal-title":"Front Aging Neurosci"},{"key":"4399_CR59","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.biopsych.2017.04.003","volume":"83","author":"JI Ayers","year":"2018","unstructured":"Ayers JI, Giasson BI, Borchelt DR (2018) Prion-like spreading in tauopathies. Biol Psychiatry 83:337\u2013346","journal-title":"Biol Psychiatry"},{"key":"4399_CR60","doi-asserted-by":"publisher","first-page":"32040","DOI":"10.1074\/jbc.M112.401240","volume":"287","author":"S Mondrag\u00f3n-Rodr\u00edguez","year":"2012","unstructured":"Mondrag\u00f3n-Rodr\u00edguez S, Trillaud-Doppia E, Dudilot A et al (2012) Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J Biol Chem 287:32040\u201332053. https:\/\/doi.org\/10.1074\/jbc.M112.401240","journal-title":"J Biol Chem"},{"key":"4399_CR61","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.4103\/1673-5374.332125","volume":"17","author":"A Torres","year":"2022","unstructured":"Torres A, Rivera B, Polanco C et al (2022) Phosphorylated tau as a toxic agent in synaptic mitochondria: implications in aging and Alzheimer\u2019s disease. Neural Regen Res 17:1645\u20131651","journal-title":"Neural Regen Res"},{"key":"4399_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21176344","volume":"21","author":"L Szabo","year":"2020","unstructured":"Szabo L, Eckert A, Grimm A (2020) Insights into disease-associated Tau impact on mitochondria. Int J Mol Sci 21:1\u201327","journal-title":"Int J Mol Sci"},{"key":"4399_CR63","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1111\/ejn.14699","volume":"53","author":"ST Feng","year":"2021","unstructured":"Feng ST, Wang ZZ, Yuan YH et al (2021) Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: implications for Parkinson\u2019s disease. Eur J Neurosci 53:2946\u20132959","journal-title":"Eur J Neurosci"},{"key":"4399_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"MP Murphy","year":"2010","unstructured":"Murphy MP, Levine H (2010) Alzheimer\u2019s disease and the amyloid-\u03b2 peptide. J Alzheimer\u2019s Dis 19:311\u2013323","journal-title":"J Alzheimer\u2019s Dis"},{"key":"4399_CR65","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y et al (2017) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38:1205\u20131235","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"4399_CR66","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13041-024-01118-1","volume":"17","author":"A Azargoonjahromi","year":"2024","unstructured":"Azargoonjahromi A (2024) The duality of amyloid-\u03b2: its role in normal and Alzheimer\u2019s disease states. Mol Brain 17(1):44","journal-title":"Mol Brain"},{"key":"4399_CR67","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1002\/alz.13379","volume":"19","author":"YG Lee","year":"2023","unstructured":"Lee YG, Jeon S, Kang SW, Ye BS (2023) Effects of amyloid beta and dopaminergic depletion on perfusion and clinical symptoms. Alzheimer\u2019s Dementia 19:5719\u20135729. https:\/\/doi.org\/10.1002\/alz.13379","journal-title":"Alzheimer\u2019s Dementia"},{"key":"4399_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1196602","author":"K Baik","year":"2023","unstructured":"Baik K, Cha J, Park M et al (2023) Distinct amyloid-dependent patterns of nigra dopamine depletion in Lewy body diseases. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2023.1196602","journal-title":"Front Aging Neurosci"},{"key":"4399_CR69","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K et al (2010) Synergistic interactions between A\u03b2, tau, and \u03b1-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30:7281\u20137289. https:\/\/doi.org\/10.1523\/JNEUROSCI.0490-10.2010","journal-title":"J Neurosci"},{"key":"4399_CR70","doi-asserted-by":"publisher","first-page":"18276","DOI":"10.1021\/jacs.3c03212","volume":"145","author":"DM Vadukul","year":"2023","unstructured":"Vadukul DM, Papp M, Thrush RJ et al (2023) \u03b1-Synuclein aggregation is triggered by oligomeric amyloid-\u03b2 42 via heterogeneous primary nucleation. J Am Chem Soc 145:18276\u201318285. https:\/\/doi.org\/10.1021\/jacs.3c03212","journal-title":"J Am Chem Soc"},{"issue":"12","key":"4399_CR71","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.3390\/ijms241210215","volume":"24","author":"M Noguchi-Shinohara","year":"2023","unstructured":"Noguchi-Shinohara M, Ono K (2023) The mechanisms of the roles of \u03b1-synuclein, amyloid-\u03b2, and tau protein in the Lewy body diseases: pathogenesis, early detection, and therapeutics. Int J Mol Sci 24(12):10215","journal-title":"Int J Mol Sci"},{"issue":"21","key":"4399_CR72","doi-asserted-by":"publisher","first-page":"12245","DOI":"10.1073\/pnas.211412398","volume":"98","author":"E Masliah","year":"2001","unstructured":"Masliah E, Rockenstein E, Veinbergs I et al (2001) \u03b2-Amyloid peptides enhance-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer\u2019s disease and Parkinson\u2019s disease. Proc Natl Acad Sci USA 98(21):12245\u201350","journal-title":"Proc Natl Acad Sci USA"},{"key":"4399_CR73","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0976500X241253648","volume":"15","author":"J Chand","year":"2024","unstructured":"Chand J, Fanai HL, Antony AS, Subramanian G (2024) Neurotoxicity by Hypoxia an Intermediate Between Alpha-synuclein and Mitochondrial Dysfunction in Parkinson\u2019s Disease. J Pharmacol Pharmacother 15:253\u2013263. https:\/\/doi.org\/10.1177\/0976500X241253648","journal-title":"J Pharmacol Pharmacother"},{"key":"4399_CR74","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0460.1000444","author":"DJ Irwin","year":"2018","unstructured":"Irwin DJ, Hurtig HI (2018) The contribution of Tau, amyloid-beta and alpha-synuclein pathology to dementia in Lewy body disorders. J Alzheimers Dis Parkinsonism. https:\/\/doi.org\/10.4172\/2161-0460.1000444","journal-title":"J Alzheimers Dis Parkinsonism"},{"key":"4399_CR75","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wei W, Zhao M et al (2021) Review interaction between a\u03b2 and tau in the pathogenesis of Alzheimer\u2019s disease. Int J Biol Sci 17:2181\u20132192. https:\/\/doi.org\/10.7150\/ijbs.57078","journal-title":"Int J Biol Sci"},{"key":"4399_CR76","doi-asserted-by":"publisher","first-page":"Article Number","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R et al (2023) Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther 8:Article Number 248","journal-title":"Signal Transduct Target Ther"},{"key":"4399_CR77","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K et al (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 26:5481\u20135503","journal-title":"Mol Psychiatry"},{"key":"4399_CR78","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.4103\/1673-5374.332127","volume":"17","author":"A Roda","year":"2022","unstructured":"Roda A, Serra-Mir G, Montoliu-Gaya L et al (2022) Amyloid-beta peptide and tau protein crosstalk in Alzheimer\u2019s disease. Neural Regen Res 17:1666\u20131674","journal-title":"Neural Regen Res"},{"key":"4399_CR79","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin DJ, Lee VMY, Trojanowski JQ (2013) Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci 14:626\u2013636","journal-title":"Nat Rev Neurosci"},{"key":"4399_CR80","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.semcdb.2018.05.005","volume":"99","author":"X Yan","year":"2020","unstructured":"Yan X, Uronen RL, Huttunen HJ (2020) The interaction of \u03b1-synuclein and Tau: a molecular conspiracy in neurodegeneration? Semin Cell Dev Biol 99:55\u201364","journal-title":"Semin Cell Dev Biol"},{"key":"4399_CR81","doi-asserted-by":"publisher","first-page":"855","DOI":"10.4103\/1673-5374.382231","volume":"19","author":"M Jin","year":"2024","unstructured":"Jin M, Wang S, Gao X et al (2024) Pathological and physiological functional cross-Talks of?-synuclein and tau in the central nervous system. Neural Regen Res 19:855\u2013862","journal-title":"Neural Regen Res"},{"key":"4399_CR82","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1074\/jbc.RA119.012284","volume":"295","author":"J Lu","year":"2020","unstructured":"Lu J, Zhang S, Ma X et al (2020) Structural basis of the interplay between \u03b1-synuclein and Tau in regulating pathological amyloid aggregation. J Biol Chem 295:7470\u20137480. https:\/\/doi.org\/10.1074\/jbc.RA119.012284","journal-title":"J Biol Chem"},{"key":"4399_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309416","author":"J Ramirez","year":"2024","unstructured":"Ramirez J, Saleh IG, Yanagawa ESK et al (2024) Multivalency drives interactions of alpha-synuclein fibrils with tau. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0309416","journal-title":"PLoS ONE"},{"issue":"7","key":"4399_CR84","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/cns.14818","volume":"30","author":"J Zhao","year":"2024","unstructured":"Zhao J, Wei M, Guo M et al (2024) GSK3: a potential target and pending issues for treatment of Alzheimer\u2019s disease. CNS Neurosci Ther 30(7):818","journal-title":"CNS Neurosci Ther"},{"key":"4399_CR85","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jns.2019.05.016","volume":"402","author":"T Guttuso","year":"2019","unstructured":"Guttuso T, Andrzejewski KL, Lichter DG, Andersen JK (2019) Targeting kinases in Parkinson\u2019s disease: a mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. J Neurol Sci 402:121\u2013130","journal-title":"J Neurol Sci"},{"key":"4399_CR86","doi-asserted-by":"publisher","unstructured":"Ga\u0327ssowska M, Czapski GA, Paja\u0137 B, et al (2014) Extracellular \u03b1-synuclein leads to microtubule destabilization via GSK-3\u03b2-dependent tau phosphorylation in PC12 cells. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0094259","DOI":"10.1371\/journal.pone.0094259"},{"key":"4399_CR87","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1111\/j.1742-4658.2011.08389.x","volume":"278","author":"F Kawakami","year":"2011","unstructured":"Kawakami F, Suzuki M, Shimada N et al (2011) Stimulatory effect of \u03b1 -synuclein on the tau-phosphorylation by GSK-3 \u03b2. FEBS J 278:4895\u20134904. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08389.x","journal-title":"FEBS J"},{"key":"4399_CR88","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1096\/fj.08-120410","volume":"23","author":"T Duka","year":"2009","unstructured":"Duka T, Duka V, Joyce JN, Sidhu A (2009) \u03b1-Synuclein contributes to GSK-3\u03b2-catalyzed Tau phosphorylation in Parkinson\u2019s disease models. FASEB J 23:2820\u20132830. https:\/\/doi.org\/10.1096\/fj.08-120410","journal-title":"FASEB J"},{"key":"4399_CR89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.phrs.2015.03.010","volume":"97","author":"M Golpich","year":"2015","unstructured":"Golpich M, Amini E, Hemmati F et al (2015) Glycogen synthase kinase-3 beta (GSK-3\u03b2) signaling: implications for Parkinson\u2019s disease. Pharmacol Res 97:16\u201326","journal-title":"Pharmacol Res"},{"key":"4399_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055972","author":"SH Ramirez","year":"2013","unstructured":"Ramirez SH, Fan S, Dykstra H et al (2013) Inhibition of glycogen synthase kinase 3\u03b2 promotes tight junction stability in brain endothelial cells by half-life extension of Occludin and Claudin-5. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0055972","journal-title":"PLoS ONE"},{"key":"4399_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31071-8","author":"PH Hsu","year":"2018","unstructured":"Hsu PH, Lin YT, Chung YH et al (2018) Focused ultrasound-induced blood-brain barrier opening enhances GSK-3 inhibitor delivery for amyloid-beta plaque reduction. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-31071-8","journal-title":"Sci Rep"},{"key":"4399_CR92","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/JCI64516","volume":"123","author":"PTT Ly","year":"2013","unstructured":"Ly PTT, Wu Y, Zou H et al (2013) Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Investig 123:224\u2013235. https:\/\/doi.org\/10.1172\/JCI64516","journal-title":"J Clin Investig"},{"key":"4399_CR93","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3389\/fnins.2015.00403","volume":"9","author":"CA Lazzara","year":"2015","unstructured":"Lazzara CA, Kim YH (2015) Potential application of lithium in Parkinson\u2019s and other neurodegenerative diseases. Front Neurosci 9:403","journal-title":"Front Neurosci"},{"key":"4399_CR94","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/cdd.2014.179","volume":"22","author":"JJ Credle","year":"2015","unstructured":"Credle JJ, George JL, Wills J et al (2015) GSK-3\u03b2 dysregulation contributes to Parkinson\u2019s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and \u03b1-synuclein. Cell Death Differ 22:838\u2013851. https:\/\/doi.org\/10.1038\/cdd.2014.179","journal-title":"Cell Death Differ"},{"key":"4399_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-00969-8","author":"Y Takaichi","year":"2020","unstructured":"Takaichi Y, Chambers JK, Inoue H et al (2020) Phosphorylation and oligomerization of \u03b1-synuclein associated with GSK-3\u03b2 activation in the rTg4510 mouse model of tauopathy. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-020-00969-8","journal-title":"Acta Neuropathol Commun"},{"key":"4399_CR96","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3892\/mmr.2014.2080","volume":"9","author":"DW Li","year":"2014","unstructured":"Li DW, Liu ZQ, Chen W et al (2014) Association of glycogen synthase kinase-3\u03b2 with Parkinson\u2019s disease (Review). Mol Med Rep 9:2043\u20132050","journal-title":"Mol Med Rep"},{"key":"4399_CR97","first-page":"4209475","volume":"2019","author":"T Jaworski","year":"2019","unstructured":"Jaworski T, Banach-Kasper E, Gralec K (2019) GSK-3\u03b2 at the intersection of neuronal plasticity and neurodegeneration. Neural Plast Neural Plast 2019:4209475","journal-title":"Neural Plast Neural Plast"},{"key":"4399_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10020230","volume":"10","author":"A Vall\u00e9e","year":"2021","unstructured":"Vall\u00e9e A, Vall\u00e9e JN, Lecarpentier Y (2021) Parkinson\u2019s disease: potential actions of lithium by targeting the WNT\/\u0392-catenin pathway, oxidative stress, inflammation and glutamatergic pathway. Cells 10:1\u201316. https:\/\/doi.org\/10.3390\/cells10020230","journal-title":"Cells"},{"key":"4399_CR99","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jnc.13365","volume":"136","author":"A Wilkaniec","year":"2016","unstructured":"Wilkaniec A, Czapski GA, Adamczyk A (2016) Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. J Neurochem 136:222\u2013233","journal-title":"J Neurochem"},{"issue":"11","key":"4399_CR100","doi-asserted-by":"publisher","first-page":"e18412","DOI":"10.1111\/jcmm.18412","volume":"28","author":"M Alrouji","year":"2024","unstructured":"Alrouji M, Al-kuraishy HM, Al-Gareeb AI et al (2024) Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease. J Cell Mol Med 28(11):e18412","journal-title":"J Cell Mol Med"},{"key":"4399_CR101","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12929-021-00774-y","volume":"28","author":"PC Pao","year":"2021","unstructured":"Pao PC, Tsai LH (2021) Three decades of Cdk5. J Biomed Sci 28:79","journal-title":"J Biomed Sci"},{"key":"4399_CR102","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1021\/acschemneuro.0c00096","volume":"11","author":"AB Allnutt","year":"2020","unstructured":"Allnutt AB, Waters AK, Kesari S, Yenugonda VM (2020) Physiological and pathological roles of Cdk5: potential directions for therapeutic targeting in neurodegenerative disease. ACS Chem Neurosci 11:1218\u20131230","journal-title":"ACS Chem Neurosci"},{"key":"4399_CR103","doi-asserted-by":"publisher","first-page":"1030639","DOI":"10.3389\/fncel.2022.951202","volume":"16","author":"C Ao","year":"2022","unstructured":"Ao C, Li C, Chen J et al (2022) The role of Cdk5 in neurological disorders. Front Cell Neurosci 16:1030639","journal-title":"Front Cell Neurosci"},{"key":"4399_CR104","doi-asserted-by":"publisher","first-page":"1030639","DOI":"10.3389\/fnmol.2022.1030639","volume":"15","author":"Z Tian","year":"2022","unstructured":"Tian Z, Feng B, Wang XQ, Tian J (2022) Focusing on cyclin-dependent kinases 5: A potential target for neurological disorders. Front Mol Neurosci 15:1030639","journal-title":"Front Mol Neurosci"},{"key":"4399_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.2","author":"L Crews","year":"2011","unstructured":"Crews L, Patrick C, Adame A et al (2011) Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer\u2019s disease. Cell Death Dis. https:\/\/doi.org\/10.1038\/cddis.2011.2","journal-title":"Cell Death Dis"},{"key":"4399_CR106","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.4103\/1673-5374.360165","volume":"18","author":"R Requejo-Aguilar","year":"2023","unstructured":"Requejo-Aguilar R (2023) Cdk5 and aberrant cell cycle activation at the core of neurodegeneration. Neural Regen Res 18:1186\u20131190","journal-title":"Neural Regen Res"},{"key":"4399_CR107","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s11064-016-1892-2","volume":"41","author":"JY Zhang","year":"2016","unstructured":"Zhang JY, Deng YN, Zhang M et al (2016) SIRT3 acts as a neuroprotective agent in rotenone-induced Parkinson cell model. Neurochem Res 41:1761\u20131773. https:\/\/doi.org\/10.1007\/s11064-016-1892-2","journal-title":"Neurochem Res"},{"key":"4399_CR108","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9703574","author":"S Michalak","year":"2017","unstructured":"Michalak S, Florczak-Wyspia\u0144ska J, Rybacka-Mossakowska J et al (2017) Mitochondrial respiration in intact peripheral blood mononuclear cells and sirtuin 3 activity in patients with movement disorders. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2017\/9703574"},{"key":"4399_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life10110289","volume":"10","author":"EE Aspholm","year":"2020","unstructured":"Aspholm EE, Mate\u010dko-Burmann I, Burmann BM (2020) Keeping \u03b1-synuclein at bay: a more active role of molecular chaperones in preventing mitochondrial interactions and transition to pathological states? Life 10:1\u201319","journal-title":"Life"},{"key":"4399_CR110","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/hmg\/ddg283","volume":"12","author":"A Iwata","year":"2003","unstructured":"Iwata A, Maruyama M, Akagi T et al (2003) Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet 12:2625\u20132635. https:\/\/doi.org\/10.1093\/hmg\/ddg283","journal-title":"Hum Mol Genet"},{"key":"4399_CR111","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fnagi.2018.00370","volume":"10","author":"G Zhang","year":"2018","unstructured":"Zhang G, Xia Y, Wan F et al (2018) New perspectives on roles of alpha-synuclein in Parkinson\u2019s disease. Front Aging Neurosci 10:370","journal-title":"Front Aging Neurosci"},{"key":"4399_CR112","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.3390\/ijms20215312","volume":"20","author":"KJ Lin","year":"2019","unstructured":"Lin KJ, Lin KL, Der CS et al (2019) The overcrowded crossroads: mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson\u2019s disease. Int J Mol Sci 20:5321","journal-title":"Int J Mol Sci"},{"key":"4399_CR113","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bph.15684","volume":"179","author":"ME Haque","year":"2022","unstructured":"Haque ME, Akther M, Azam S et al (2022) Targeting \u03b1-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson\u2019s disease. Br J Pharmacol 179:23\u201345","journal-title":"Br J Pharmacol"},{"key":"4399_CR114","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/biom11050718","volume":"11","author":"P Risiglione","year":"2021","unstructured":"Risiglione P, Zinghirino F, Di Rosa MC et al (2021) Alpha-synuclein and mitochondrial dysfunction in Parkinson\u2019s disease: the emerging role of vdac. Biomolecules 11:718","journal-title":"Biomolecules"},{"key":"4399_CR115","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s13311-013-0182-9","volume":"10","author":"K Nakamura","year":"2013","unstructured":"Nakamura K (2013) \u03b1-Synuclein and mitochondria: partners in crime? Neurotherapeutics 10:391\u2013399","journal-title":"Neurotherapeutics"},{"key":"4399_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03241-9","author":"T Ryan","year":"2018","unstructured":"Ryan T, Bamm VV, Stykel MG et al (2018) Cardiolipin exposure on the outer mitochondrial membrane modulates \u03b1-synuclein. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-018-03241-9","journal-title":"Nat Commun"},{"key":"4399_CR117","doi-asserted-by":"publisher","first-page":"578993","DOI":"10.3389\/fnins.2020.578993","volume":"14","author":"V Gilmozzi","year":"2020","unstructured":"Gilmozzi V, Gentile G, Castelo Rueda MP et al (2020) Interaction of alpha-synuclein with lipids: mitochondrial cardiolipin as a critical player in the pathogenesis of Parkinson\u2019s disease. Front Neurosci 14:578993","journal-title":"Front Neurosci"},{"key":"4399_CR118","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.plipres.2015.10.005","volume":"61","author":"S Ghio","year":"2016","unstructured":"Ghio S, Kamp F, Cauchi R et al (2016) Interaction of \u03b1-synuclein with biomembranes in Parkinson\u2019s disease\u2014role of cardiolipin. Prog Lipid Res 61:73\u201382","journal-title":"Prog Lipid Res"},{"key":"4399_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06251-8","author":"O Lurette","year":"2023","unstructured":"Lurette O, Mart\u00edn-Jim\u00e9nez R, Khan M et al (2023) Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-023-06251-8","journal-title":"Cell Death Dis"},{"issue":"11","key":"4399_CR120","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.3390\/cells10113022","volume":"10","author":"M Vizziello","year":"2021","unstructured":"Vizziello M, Borellini L, Franco G, Ardolino G (2021) Disruption of mitochondrial homeostasis: the role of pink1 in Parkinson\u2019s disease. Cells 10(11):3022","journal-title":"Cells"},{"issue":"9","key":"4399_CR121","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/jcm8091377","volume":"8","author":"M Repici","year":"2019","unstructured":"Repici M, Giorgini F (2019) DJ-1 in Parkinson\u2019s disease: clinical insights and therapeutic perspectives. J Clin Med 8(9):1377","journal-title":"J Clin Med"},{"key":"4399_CR122","doi-asserted-by":"publisher","first-page":"105837","DOI":"10.1016\/j.nbd.2022.105837","volume":"173","author":"A Oun","year":"2022","unstructured":"Oun A, Sabogal-Guaqueta AM, Galuh S et al (2022) The multifaceted role of LRRK2 in Parkinson\u2019s disease: from human iPSC to organoids. Neurobiol Dis 173:105837","journal-title":"Neurobiol Dis"},{"issue":"13","key":"4399_CR123","doi-asserted-by":"publisher","first-page":"7030","DOI":"10.3390\/ijms22137030","volume":"22","author":"GE Moya","year":"2021","unstructured":"Moya GE, Rivera PD, Dittenhafer-reed KE (2021) Evidence for the role of mitochondrial dna release in the inflammatory response in neurological disorders. Int J Mol Sci 22(13):7030","journal-title":"Int J Mol Sci"},{"key":"4399_CR124","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3390\/molecules24081583","volume":"24","author":"A Singh","year":"2019","unstructured":"Singh A, Kukreti R, Saso L, Kukreti S (2019) Oxidative stress: a key modulator in neurodegenerative diseases. Molecules 24:1583","journal-title":"Molecules"},{"issue":"7","key":"4399_CR125","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1089\/ars.2010.3359","volume":"14","author":"G Z\u00fc","year":"2011","unstructured":"Z\u00fc G, Reiser G (2011) Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection. Antioxid Redox Signal 14(7):1275\u201388","journal-title":"Antioxid Redox Signal"},{"key":"4399_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.654785","author":"D Yang","year":"2021","unstructured":"Yang D, Ying J, Wang X et al (2021) Mitochondrial dynamics: a key role in neurodegeneration and a potential target for neurodegenerative disease. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2021.654785","journal-title":"Front Neurosci"},{"issue":"3","key":"4399_CR127","doi-asserted-by":"publisher","first-page":"e13012","DOI":"10.1111\/bpa.13012","volume":"32","author":"Z Chen","year":"2022","unstructured":"Chen Z, Rasheed M, Deng Y (2022) The epigenetic mechanisms involved in mitochondrial dysfunction: Implication for Parkinson\u2019s disease. Brain Pathol 32(3):e13012","journal-title":"Brain Pathol"},{"key":"4399_CR128","first-page":"617472","volume":"2011","author":"P Teismann","year":"2011","unstructured":"Teismann P, Mounsey RB (2011) Mitochondrial dysfunction in Parkinson\u2019s disease: Pathogenesis and neuroprotection. Parkinsons Dis 2011:617472","journal-title":"Parkinsons Dis"},{"key":"4399_CR129","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.neuro.2019.07.007","volume":"74","author":"L Mezzaroba","year":"2019","unstructured":"Mezzaroba L, Alfieri DF, Colado Sim\u00e3o AN, Vissoci Reiche EM (2019) The role of zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology 74:230\u2013241","journal-title":"Neurotoxicology"},{"key":"4399_CR130","doi-asserted-by":"crossref","unstructured":"Prasuhn J, Davis RL, Kumar KR (2021) Targeting Mitochondrial Impairment in Parkinson\u2019s Disease: Challenges and Opportunities. Front Cell Dev Biol 8","DOI":"10.3389\/fcell.2020.615461"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04399-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-025-04399-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04399-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T17:02:31Z","timestamp":1750698151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-025-04399-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4399"],"URL":"https:\/\/doi.org\/10.1007\/s11064-025-04399-7","relation":{"references":[{"id-type":"doi","id":"10.1155\/2017\/9703574","asserted-by":"subject"}]},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}],"article-number":"145"}}